ReviewNeurosurgery clinics of North America2010
Dendritic cell vaccines for brain tumors.
Review in Neurosurgery clinics of North America, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 52 citations in OpenAlex.
- Delivery strategies for cell-based therapies in the brain: overcoming multiple barriers.Drug delivery and translational research · 2021Article
- Bioengineered recombinant vault nanoparticles coupled with NY-ESO-1 glioma-associated antigens induce maturation of native dendritic cells.Journal of neuro-oncology · 2020Article
- Immunotherapy for Medulloblastoma: Current Perspectives.ImmunoTargets and therapy · 2020Review
- The role of the immune system in brain metastasis.Current neurobiology · 2019Article
- Therapeutic Interventions in Adult Low-Grade Gliomas.Journal of clinical neurology (Seoul, Korea) · 2019Review
- Dendritic Cells as an Alternate Approach for Treatment of Neurodegenerative Disorders.Cellular and molecular neurobiology · 2018Review
- miR-181d regulates human dendritic cell maturation through NF-κB pathway.Cell proliferation · 2017Article
- Engineering challenges for brain tumor immunotherapy.Advanced drug delivery reviews · 2017Review
- Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme.Journal of neuro-oncology · 2015Review
- Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme.BioMed research international · 2015Review
- Natural killer cells eradicate galectin-1-deficient glioma in the absence of adaptive immunity.Cancer research · 2014Article
- Extracellular vesicles shed by glioma cells: pathogenic role and clinical value.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Review
- Immunomodulatory effects of hemagglutinin- (HA-) modified A20 B-cell lymphoma expanded as a brain tumor on adoptively transferred HA-Specific CD4+ T cells.TheScientificWorldJournal · 2014Article
- Dendritic cell vaccination for glioblastoma multiforme: review with focus on predictive factors for treatment response.ImmunoTargets and therapy · 2014Review
- Cell-based immunotherapy against gliomas: from bench to bedside.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Review
- Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas.Anticancer research · 2013Article
- Dendritic cell vaccination in glioblastoma after fluorescence-guided resection.World journal of clinical oncology · 2012Article
- Article
- Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2012Article
- Medulloblasoma: challenges for effective immunotherapy.Journal of neuro-oncology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Over the past decade, dendritic cell-based immunotherapy for central nervous system tumors has progressed from preclinical rodent models and safety assessments to phase I/II clinical trials in over 200 patients, which have produced measurable immunologic responses and some prolonged survival rates. Many questions regarding the methods and molecular mechanisms behind this new treatment option, however, remain unanswered. Results from currently ongoing and future studies will help to elucidate which dendritic cell preparations, treatment protocols, and adjuvant therapeutic regimens will optimize the efficacy of dendritic cell vaccination. As clinical studies continue to report results on dendritic cell-mediated immunotherapy, it will be critical to continue refining treatment methods and developing new ways to augment this promising form of glioma treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.